Skip to main content
S&P 5007,704.81+1.80%DOW53,258.14+2.84%NASDAQ25,884.14+2.02%BTC$80,535.00+3.76%ETH$2,432.59+6.02%GOLD$4,078.30+3.50%OIL$88.78-7.61%
Smart Investors Daily
SID Premium
SE

NASDAQ · SEPN

Septerna, Inc. Common Stock

Healthcare · Biotechnology

$43.70

Up+$3.07 (+7.03%)

Updated Nov 4, 2026, 5:41 PM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.17B
P/E ratio
-19.76
Dividend yield
0.00%
52-week range
$17.55 – $51.10
Volume
307.84K
Avg. volume
331.52K

Price performance · SEPN

SEPN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

SEPN closed at $43.70 after 21 trading sessions, up 22.51% for the selected period.

Last close
$43.70
Period change
+22.51%
Period low
$35.67
Period high
$45.23
Daily close
View OHLC price history
SEPN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$43.53$44.58$42.22$43.70307.84K
Nov 2, 2026$44.06$44.95$41.07$43.20475.33K
Oct 30, 2026$45.00$45.4315$43.68$44.00223.45K
Oct 29, 2026$44.43$45.60$43.74$45.23200.69K
Oct 28, 2026$43.51$45.08$41.92$44.25380.14K
Oct 27, 2026$41.43$44.22$40.97$44.14261.83K
Oct 26, 2026$40.42$41.95$38.393$41.38279.43K
Oct 23, 2026$40.63$41.21$39.65$40.41200.32K
Oct 22, 2026$40.72$41.77$39.70$40.88251.11K
Oct 21, 2026$39.57$41.40$38.75$40.76286.4K
Oct 20, 2026$36.46$39.55$36.25$39.35418.31K
Oct 19, 2026$36.48$37.82$36.035$36.38410.19K
Oct 16, 2026$37.47$37.47$35.09$36.35234.14K
Oct 15, 2026$36.78$38.36$36.22$37.45271.44K
Oct 14, 2026$36.00$37.275$34.36$36.32369.98K
Oct 13, 2026$37.49$38.51$36.275$36.415491.85K
Oct 12, 2026$38.32$38.41$37.25$37.56207.56K
Oct 9, 2026$36.76$38.73$35.765$38.37349.48K
Oct 8, 2026$35.47$37.09$34.663$36.90745.39K
Oct 7, 2026$35.27$37.14$35.20$36.001.03M
Oct 6, 2026$37.97$38.69$35.60$35.67491.2K

Latest SEPN news

The latest Smart Investors Daily articles mentioning SEPN.

Stock researchCompany · Overview

SEPN research

Overview

Company profile and research snapshot.

Company profile

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$28.00
Implied upside
—
Analysts
—
SEPN recent ratings
DateFirmRatingTarget
Aug 19, 2026JP MorganOverweight—
Aug 13, 2026Jones TradingBuy—
Aug 12, 2026Wells FargoOverweight—
Aug 12, 2026HC Wainwright & Co.Buy—
Aug 11, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 3, 2026

Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026: Guggenheim 3rd Annual Healthcare Innovation Conference – BostonFireside chat on Tuesday, November 10, 2026, at 10:00 a.m. ET Stifel 2026 Healthcare Conference – New YorkFireside chat

Yahoo · Oct 28, 2026

Is Septerna (SEPN) Stock Too Rich, Or Still Reasonable?

Septerna has delivered a sharp share-price run over the past year, and that leaves investors asking whether the current market value is adequately grounded in its sales. With the stock now drawing more attention, the key issue is how much revenue the business is actually producing to back up that enthusiasm. Septerna has returned 97.8% over the past year, which puts a lot of weight on the question of how much sales performance can justify that kind of move. The business model and execution...

Yahoo · Sep 14, 2026

Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?

Septerna (SEPN) heads into a busy conference stretch, with investor attention drawn to upcoming presentations at Wells Fargo’s 21st Annual Healthcare Conference on September 8 and Cantor Fitzgerald’s Global Healthcare Conference on September 10. At a last close of US$38.51, Septerna’s recent moves tell a mixed story, with the share price return up 2.01% over 1 day and 4.79% over 7 days, yet down 13.46% over 30 days. The year to date share price return of 37.63% and 1 year total shareholder...

Yahoo · Sep 10, 2026

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s common stock to Rajiv Patni, M.D., the Company’s newly appointed Chief Medical Officer, under the Company’s 2026 Inducement Plan (the “Inducement Plan”). The inducement grant was effective as of September 8, 2026. The award was granted as an inducement material to Dr. Patni’s employme

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By